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In 2008, vaccination against HPV was started in various 
European countries. It is worth pointing out that in Italy 
this vaccination was introduced into the already-estab-
lished national program of immunization through an 
unusual series of consultations and measures:
• On January 11, 2007, the General Direction for 
Public Health requested the opinion of the Supreme 
Health Council (Consiglio Superiore di Sanità). The 
Council advised a national program of vaccination 
free of charge for 12-year-old girls.
• On February 28, 2007, the Italian Drug Agency (AI-
FA) introduced the two HPV vaccines authorized in 
Italy into the group of medicines distributed free of 
charge by the National Health Service to 12-year-old 
girls (H-RR category).
• On December 20, 2007, a protocol was agreed upon 
by the Ministry of Health, the Italian Regions and the 
Autonomous Provinces (Strategy for free vaccination 
against HPV-infection in Italy). The agreement esta-
blished that the Regions should, through their organi-
zational models, commit themselves to offering HPV 
vaccination free of charge to 12-year-old girls. It was 
also agreed that this service could be supplemented by 
providing for the vaccination of other young females, 
either free of charge or through co-payment.
The Italian Regions subscribed to the agreement and, 
through specific deliberations, organized their vaccina-
tion campaigns.
The choices made by the Regions are summarized in 
Table I.
The Regions also chose which of the two authorized 
vaccines (Gardasil and Cervarix) to administer.
As in other countries, the choice, which involved con-
siderable economic interests, was difficult. Indeed, the 
Tab. I. HPV vaccination strategies by Italian regions.
Region Free vaccination 
with active offer
(age class [years])
Free vaccination 
with not active 
offer (age class 
[years])
Co-payment
(age class 
[years])
Vaccine Regional deliberation
Abruzzo 12 13-26 Gardasil DGR n. 1359 27/12/2007
Basilicata 12, 15, 18 and 25 13-26 Gardasil DGR n. 838 11/06/2007
Bolzano 12 13-26 Gardasil DGR n. 4699 28/12/2007
Calabria 12 13 Cervarix Nota Regionale 13/11/2007 
Campania 12 Gardasil Circolare Regionale 02/08/2007
Emilia Romagna 12 13 14-17 Cervarix DGR n. 236 25/02/2008
Friuli Venezia Giulia 12 and 16 17 Cervarix DGR n. 856 15/05/2008
Lazio 12 13 14-26 Gardasil DGR n. 133 29/02/2008
Liguria 12 13 14-26 Cervarix DGR n. 54 25/01/2008 Nota inte-
grativa Prot n. PG/2008/173464 del 
30/12/2008
Lombardia 12 Gardasil DGR n. VIII/006683 del 27/02/2008
Marche 12 13 14-17 Cervarix DGR n. 433 26/03/2008
Molise 12 13 14-26 Gardasil DGR n. 368 08/04/2008
Piemonte 12 and 16 Cervarix DGR n. 8-8167 del 11/02/2008
Puglia 12 Cervarix DGR n. 245 26/02/2008
Sardegna 12 13-17 Cervarix Deliberazione 32/12 04/06/2008
Sicilia 12 13 14-26 Cervarix/ 
Gardasil
Decreto Assessoriale 29/02/2008
Toscana 12 and 16 13, 14 and 15 Cervarix DGR n. 1020 27/12/2007 and DGR 
n. 856 27/10/2008
Trento 12 13-26 Gardasil Comunicato n. 2336 22/08/2008
Umbria 12 13 14-17 Cervarix DGR n. 84 04/02/2008
Valle d’Aosta 12 and 16 13 Cervarix DGR n. 2371 31/08/2007
Veneto 12 13 14-26 Gardasil DGR n. 411 26/02/2008 Protocollo 
Generale 07/58302 18/06/2007
EDITORIAL
2
criteria used by the decision-makers were, and still are, 
vigorously debated.
In view of the importance of this vaccination to public 
health and the ethical issues involved, the editorial staff 
of our journal has decided to open a free forum on HPV 
vaccination. It seems particularly important to sustain 
the vaccination campaign in such a way as to reach 
high coverage rates as soon as possible, and to create 
a specific system for the surveillance of HPV-diseases 
and for the evaluation of the vaccination performances. 
Furthermore, it is crucial to consider that some im-
portant questions regarding HPV vaccination are still 
open, such as the duration of protection, the possible 
need for a booster dose at some time after comple-
tion of the first vaccination cycle, the establishment 
of a protective serological correlate, the best policy 
to implement in the various epidemiological contexts, 
the most effective prophylactic use of vaccination and 
screening tests and how to vaccinate women both in 
developed countries and in developing ones.
To this regard the Journal will invite Italian and inter-
national professionals to write reviews concerning this 
subject.
The Journal wants also to celebrate the 50th year of life 
and on this occasion the Editorial Board wants to con-
firm the aim of the Journal, which is to provide a con-
tinuous update of the scientific and practical knowledge 
in Public Health field.
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